Zydus Lifesciences Limited (BOM:532321)
1,084.35
+13.45 (1.26%)
At close: Jun 22, 2026
Zydus Lifesciences Revenue
In the fiscal year ending March 31, 2026, Zydus Lifesciences had annual revenue of 271.48B INR with 16.81% growth. Zydus Lifesciences had revenue of 75.87B in the quarter ending March 31, 2026, with 16.22% growth.
Revenue
271.48B
Revenue Growth
+16.81%
P/S Ratio
4.02
Revenue / Employee
9.72M
Employees
27,917
Market Cap
1.09T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 271.48B | 39.07B | 16.81% |
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 335.93B |
| Lupin | 279.58B |
| Torrent Pharmaceuticals | 139.80B |
| Jubilant Pharmova | 82.80B |
| Abbott India | 69.29B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
Zydus Lifesciences News
- 2 days ago - Zydus Lifesciences sees significant buyback participation from promoters - Business Upturn
- 3 days ago - Zydus Lifesciences completes Rs 1,100 crore buyback extinguishing over 87 lakh shares - Business Upturn
- 5 days ago - Top stocks for trade today, June 17: Infosys, Wipro, TCS, Zydus Lifesciences, Bharat Forge and more - Business Upturn
- 6 days ago - Zydus Lifesciences completes merger with Assero Holdings for USD 166.33 million - Business Upturn
- 6 days ago - Zydus completes acquisition of Assertio Holdings for $23.50 per share - Business Upturn
- 13 days ago - Zydus Lifesciences reports significant reduction in GST demand for subsidiary - Business Upturn
- 19 days ago - Zydus Lifesciences receives USFDA warning letter for Baddi manufacturing facility - Business Upturn
- 19 days ago - Pharma sector stocks today, June 3: Natco Pharma falls 2.57%, Zydus Lifesciences falls 1.26%, Alembic Pharma down 1.06% - Business Upturn